This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Group:SMART:Greenwood SMART Team
From Proteopedia
2008-2009 SMART Team Project: GLP-1R with Exendin
| |||||||||
| 3c59, resolution 2.30Å () | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sites: | |||||||||
| Ligands: | |||||||||
| Non-Standard Residues: | |||||||||
| Gene: | Glucagon-like peptide-1 receptor(GLP1R) (Homo sapiens) | ||||||||
| Related: | 3c5t | ||||||||
| |||||||||
| |||||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||||
Type 2 diabetes is characterized by chronically elevated blood glucose levels resulting from impaired insulin function. This results, in part, from low levels of the natural hormone, glucagon like peptide-1 (GLP-1). GLP-1 binds to and activates the GLP-1 receptor (GLP-1R) resulting in increased insulin synthesis and secretion which serves to reduce blood glucose levels. As a result, the GLP-1 receptor has become an important therapeutic target for the treatment of type 2 diabetes. The synthetic Exendin-4 has a higher affinity for the receptor. Due to the differences in structure, Exendin-4 has no longer duration of action, therefore releasing more insulin. An important feature of the GLP-1R is the N-terminal extracellular domain (NTD). A two-step mechanism occurs through GLP-1 binding to the NTD and receptor activation via the core domain of the receptor. In the first step of binding, hydrogen bonds are formed between the NTD and Exendin-4. By understanding the nature of GLP-1R activation, therapeutic drugs could be developed to stimulate insulin production.
